Improvement of flow-cytometric detection of multidrug-resistant cells by cell-volume normalization of intracellular daunorubicin content.
To improve the ability of flow cytometry to detect multidrug-resistant cells, we studied the extent to which cell volume heterogeneity accounts for the variance of intracellular daunorubicin (DNR) content. For P388 murine or HL-60 human leukemia cells exposed to DNR (1 micrograms/ml, 60 min), log intracellular DNR content varied in direct proportion to log cell volume measured by flow cytometry, with a correlation coefficient of .9. This relationship was confirmed by cell sorting based on intracellular DNR content with subsequent volume determination of the sorted cells. Normalization of intracellular DNR content for cell volume (thus obtaining intracellular DNR concentration) was accomplished by subtracting log cell volume from log intracellular DNR content for each cell. This resulted in a 34% decrease (range 23-58%) in standard deviation compared to DNR content measurements without volume normalization for all cell types tested. Following exposure to DNR (as above), intracellular DNR content of drug-sensitive P388 or HL-60 cells measured by flow cytometry was 12- and 8-fold greater than that of the multidrug-resistant sublines P388/ADR and HL-60/AR, respectively. However, because of the variance of intracellular DNR content, the predictive value of flow-cytometric determination of intracellular DNR content as a discriminant assay for detecting the frequency of drug-resistant cells in a mixed population was acceptable only when the frequency of resistant cells in the population exceeded 10%. In contrast, volume normalization of intracellular DNR content enhanced the ability of the flow-cytometric assay to discriminate resistant cells by 10-fold for P388 cells and 100-fold for HL-60 cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Ross
D D
DD
Laboratory of Developmental Therapeutics, University of Maryland Cancer Center, Baltimore 21201.
Thompson
B W
BW
Ordóñez
J V
JV
Joneckis
C C
CC
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis / Q000627:therapeutic use; D003630:Daunorubicin / Q000032:analysis* / Q000627:therapeutic use; D004351:Drug Resistance; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D007938:Leukemia / Q000378:metabolism; D051379:Mice; D011237:Predictive Value of Tests; D014407:Tumor Cells, Cultured / Q000032:analysis*
D000970:Antineoplastic Agents; D003630:Daunorubicin